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RESPIRATORY-RELATED DISORDERS - Cost Studies
PRS4
PubLIC HEALTH AnD ECOnOmIC ImPACT Of 13-VALEnT PnEumOCOCCAL 
COnjugATE VACCInE (PCV13) In PubLIC AnD PRIVATE SYSTEm VERSuS PPSV23 
AnD nO VACCInATIOn In OLDER ADuLTS
Ferreira CN1, Santana CF2, Rufino C1
1Pfizer Brasil, São Paulo, Brazil, 2Pfizer, São Paulo, Brazil
Objectives: Pneumococcal disease is a public health concern worldwide. This study 
evaluates the public health and economic impact of 13-valent pneumococcal con-
jugate vaccine (PCV13) vaccination in Brazilian adults aged ≥ 50 years. MethOds: 
A cohort model with a Markov-type process depicting expected risk, consequences 
and costs of pneumococcal disease was developed. PCV13 effectiveness was based 
on data from CAPiTA; the 23-valent polysaccharide vaccine (PPSV23) effectiveness 
was based on published literature. Pneumococcal disease rates were based on data 
from DATASUS. Outcomes, direct and indirect costs (in BRL) were evaluated from a 
Brazilian public (n= 20,228,045) and private (n= 11,396,682) payer perspective over 
a 5 year time horizon. Results: From a public payer perspective, vaccination with 
PCV13 versus PPSV23 avoided 676,031 PD cases, 853 deaths with BRL 2,32 million 
cost saving. An expected 696.970 PD cases and 29.644 deaths would be avoided for 
PCV13 versus no vaccine 2,16 million cost savings. From a private payer perspec-
tive, vaccination with PCV13 versus PPSV23 avoided 410,302 PD cases and 1,074 
deaths with a 1.27million cost-savings. An expected 420,159 PD cases and 18,482 
deaths would be avoided for PCV13 versus no vaccine with a 1.69 million cost-
savings. cOnclusiOns: PCV13 prevents more pneumococcal disease cases and 
deaths than PPSV23 or no vaccine and is expected to save economic resources (direct 
and indirect) from a private perspective, and cost-effective from a public perspective.
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COSTO DE TubERCuLOSIS En LOS ESTAbLECImIEnTOS DE SALuD DEL PERú
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ObjectivOs: Estimar los costos de la Tuberculosis (TBC) en los establecimien-
tos del Ministerio de Salud del Perú. MetOdOlOgíAs: Se realizó una evaluación 
económica parcial de tipo costo de enfermedad (CE). La población de estudio fue 
una cohorte hipotética de pacientes afiliada al Seguro Público de Salud (Seguro 
Integral de Salud) en el Perú. Los costos se estimaron desde la perspectiva del 
financiador tomados para el año 2014. La definición de los esquemas de manejo 
clínico (procedimientos médicos y medicamentos para el diagnóstico, tratami-
ento y seguimiento de la enfermedad) provienen de las Condiciones Asegurables 
del Plan Esencial de Aseguramiento en Salud (PEAS). Cada esquema de manejo 
clínico se ha estimado con la metodología de costeo estándar. El costo total 
fue ajustado por factores de oferta, demanda y adherencia. ResultAdOs: La 
cohorte hipotética de TBC es de 13,808 personas para el año 2014 (Incidencia 
de TBC Pulmonar: 0.11%, incidencia de TBC Extrapulmonar: 0.02%, incidencia 
de TBC con complicaciones: 0.01%, incidencia de TBC Multidrogoresistente: 
0.0036%). El costo total para TBC es de 27,443,865 dólares correspondiendo 
para TBC Pulmonar 23,666,252 dólares, TBC Extrapulmonar 1,501,742 dólares, 
TBC con complicaciones 935,552 dólares y para TBC Multidrogoresistente es 
de 1,340,319 dólares. El costo total correspondiente a diagnóstico es 1,302,884 
dólares (4.7%), tratamiento 24, 205,776 dólares (88.2%) y para seguimiento 1,935,206 
dólares (7.1%). El costo fijo correspondió a 12,538,706 dólares (45.7%) y el costo 
variable a 14,905,159 dólares (54.3%). cOnclusiOnes: El costo anual total para 
Tuberculosis en el Perú se estimó en 27,443,865 dólares. Este monto representa 
el 14.1% del presupuesto ejecutado el año 2014 en el Programa Presupuestal 016 
TBC –VIH/SIDA.
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Objectives: The objective of study is to measure the cost of illness (out of 
pocket costs paid by patients) for T.B in Quetta city, Pakistan. MethOds: Cross 
sectional study was performed on TB patient in Fatima Jinnah chest hospi-
tal Quetta. The TB patients who were registered in hospital were interviewed 
to determine the out of pocket cost paid by TB patients by using standardized 
data collection tool. The descriptive statistics was used to present the data. All 
analyses were performed using SPSS 20.0. Results: The total of 70 TB patients 
were agree to participate in the study. Majority (62%, n= 44) were females with 
rural residency 51.4%, n= 36). Majority of patients had monthly income were 
8000-15000. The total average out of pocket cost was Pk. Rs. 11,685 per month 
for an individual patient. In addition, it was calculated that a patient spend Pk. 
Rs. 292 for diagnostic tests including chest x-ray, additional medicine purchased 
were of Pk. Rs. 1465, travel cost were Pk. Rs. 3,485 , special food cost were Pk. 
Rs. 2,128 rupees accommodation cost were Pk. Rs. 3,825 rupees, & the other 
cost were Pk. Rs. 490. It is worth mentioning here that all the medication and 
other treatment cost is paid by the government. cOnclusiOns: The study con-
cluded that although government paid all the medication and other treatment 
cost for TB patients, yet patient had to bear a high amount of money from his 
pocket which put additional burden to the poor patient suffering with a disease 
like TB.
12.5 million). cOnclusiOns: Colombian decision makers in health could largely 
benefit by controlling relapses for these types of patients. This study is one of the 
first approaches at quantifying the impact of the disease and its relapse. Policy 
measures should consider this data for addressing mental health in a systematic 
and conjoint approach.
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
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Objectives: 1. To study health effect of smoking by questionnaires and tests. 
2. To study by comparing smoking population’s function of the lung with non-
smoker’s function of the lung. MethOds: 1201 people has participated for the 
research study and they were 20-39 years of age, and older than 40 years old, also 
study has taken in Ulaanbaatar at the same time. Research study included 79 
questions from “Adult core questionnaire” study of chronic respiratory diseases 
in the Asia-Pacific and spirometer analysis has done too. Results: The smok-
ing population by age and gender in Ulaanbaatar. AGE Male Smoking/%/ Female 
Smoking/%/ 20-29 194 75.5 161 19.4 30-39 121 79.3 134 28.4 40-49 153 78.4 152 
24.4 cOnclusiOns: Research study shows that 49.4% of total population and 
76.9% of males, 21.4% of females have been smoking for their lives with some 
circumstances in Ulaanbaatar. Also study shows that 30-39 years old, 70 years 
old females are smoking more than other ages particularly. For males smoking is 
in equal level for all ages. Function of lungs has changed depending on smoking 
and total years of smoking.
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fLuTICASOnE PROPIOnATE VERSuS buDESOnIDE OR bECLOmETHASOnE AS 
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Objectives: compare the efficacy and the safety of fluticasone propionate in the 
management of moderate to severe asthma in adults and children to the inhaled 
corticosteroids currently available in the public health care system in order to 
present an alternative therapy to the Brazilian government. MethOds: a sys-
tematic review of the MEDLINE, the Cochrane Library and Centre for Reviews and 
Dissemination (CRD) databases was conducted until September 2014, including 
randomized clinical study and systematic reviews about comparison between flu-
ticasone propionate and budesonide or beclomethasone, not associated with other 
medications. There was no age limit and the assessed endpoint was pulmonary 
function through morning and evening Peak Expiratory Flow Rate, Forced Expiratory 
Volume in one second, exacerbation and adverse events. The quality of the stud-
ies was measured by Grades of Recommendation, Assessment, Development and 
Evaluation. Results: there were 788 articles identified in MEDLINE, 231 in The 
Cochrane library and 46 in CRD, among all of these, 259 were duplicates, remaining 
806 to title analysis. In the final analysis, 21 articles were included – 3 system-
atic reviews and 18 randomized clinical studies. All systematic reviews showed a 
strong recommendation in favor of the new technology and high methodological 
quality. Among the clinical studies, 9 of them compared fluticasone propionate 
to beclomethasone and the others 9 to budesonide. The study results showed no 
statistically significant difference between the compared medicines. According to 
the results, fluticasone propionate is effective and well tolerated for the treatment 
of moderate to severe asthma, in adults and children, as well as beclomethasone 
and budesonide. cOnclusiOns: from this perspective, the inclusion of fluticasone 
propionate in the Brazilian Clinical Protocol and Therapeutic Guidelines could rep-
resent an extension of the therapeutic arsenal, especially, for the pediatric popula-
tion that have few options of treatment. Funding for this study was provided by 
GlaxoSmithKline, study HO-14-15763.
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Objectives: Non infectious chronic diseases become one of the most frequent 
cause of morbidity all around the world and they are results of interactions 
between man and his environment. This group of diseases includes also chronic 
obstructive pulmonary disease (COPD), which explains why medications for the 
treatment of this disease take a large part in the consumption. The aim of this 
study was to analyze the consumption of medications in COPD in Serbia and 
in Norway in period from 2007 to 2012. MethOds: The data about the use of 
medications in Serbia were taken from the Agency for Drugs and Medical Devices 
of the Republic of Serbia. The data about the use of medications in Norwey were 
taken from official website of the Norwegian healthcare system. Results: Total 
consumption of medications for the treatment of respiratory diseases in Serbia 
from 2007 to 2012 was lower than the comnsumption of the same medications in 
Norway in the same time of period. The utilized medications of R group in both 
countries was very uneven in this period of time. Between the subgroups, the most 
frequently used medications were those for the chronic obstructive pulmonary 
disease (R03). cOnclusiOns: The consumption of medications in Serbia from 
2007 to 2012 was higher than in Norway. While analysing the consumption of 
medications we can make conclusion that the structure of the utilized medica-
tions in Serbia is not appropriate and is not similar to the farmacoterapeutic 
practice in well developed Norway. This research was supported by Provincial 
